Parkinson's Disease DNA Damage Repair Therapeutic Companies

Migration, Crosslink

📖

Parkinson's Disease DNA Damage Repair Therapeutic Companies

active

wiki page Created: 2026-04-02T07:20:07 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-pd-dna-damage-repair-ther

📖 Wiki Page

company850 wordssynced 2026-04-02

Overview

flowchart TD companies_pd_dna_damage_repair["Parkinsons Disease DNA Damage Repair Therapeuti"] style companies_pd_dna_damage_repair fill:#4fc3f7,stroke:#333,color:#000 companies_pd_dna_dam_0["Key Mechanisms"] companies_pd_dna_damage_repair -->|"includes"| companies_pd_dna_dam_0 style companies_pd_dna_dam_0 fill:#81c784,stroke:#333,color:#000 companies_pd_dna_dam_1["PARP Inhibition and NAD+ Restoration"] companies_pd_dna_damage_repair -->|"includes"| companies_pd_dna_dam_1 style companies_pd_dna_dam_1 fill:#ef5350,stroke:#333,color:#000 companies_pd_dna_dam_2["Base Excision Repair Enhancement"] companies_pd_dna_damage_repair -->|"includes"| companies_pd_dna_dam_2 style companies_pd_dna_dam_2 fill:#ffd54f,stroke:#333,color:#000 companies_pd_dna_dam_3["Nucleotide Excision Repair"] companies_pd_dna_damage_repair -->|"includes"| companies_pd_dna_dam_3 style companies_pd_dna_dam_3 fill:#ce93d8,stroke:#333,color:#000 companies_pd_dna_dam_4["Companies Developing PD DNA Damage Repair Therap"] companies_pd_dna_damage_repair -->|"includes"| companies_pd_dna_dam_4 style companies_pd_dna_dam_4 fill:#4fc3f7,stroke:#333,color:#000 companies_pd_dna_dam_5["Life Biosciences"] companies_pd_dna_damage_repair -->|"includes"| companies_pd_dna_dam_5 style companies_pd_dna_dam_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

DNA damage accumulation in dopaminergic neurons is a central pathological feature in [Parkinson's disease](/diseases/parkinsons-disease). The high metabolic activity of these neurons, combined with mitochondrial dysfunction and oxidative stress, creates a perfect storm for genomic instability. Evidence shows that DNA repair pathways are impaired in PD patients, and enhancing DNA repair capacity represents a promising therapeutic strategy["@dna-pd-repair"].

This page catalogs companies developing DNA damage repair therapies specifically for Parkinson's disease, including:

PARP inhibitors for neuroprotection
NAD+ precursors to support DNA repair enzymes
Direct DNA repair enzyme replacement
Genome maintenance and chromatin remodeling approaches

Key Mechanisms

PARP Inhibition and NAD+ Restoration

Poly(ADP-ribose) polymerases (PARPs) are activated by DNA damage to facilitate repair. However, excessive PARP activation depletes cellular NAD+ and ATP, leading to cell death (parthanatos). PARP inhibition protects neurons while preserving DNA repair capacity[@parp-neuroprotection]. Additionally, NAD+ precursors like NMN and NR boost SIRT1 activity and DNA repair capacity[@nad-precursors].

Base Excision Repair Enhancement

The base excision repair (BER) pathway is particularly important for repairing oxidative DNA damage (8-oxoguanine), which accumulates in PD brains. Enhancing BER enzymes like OGG1, APE1, and polymerase β could prevent mutation accumulation.

Nucleotide Excision Repair

Transcription-coupled NER is crucial for repairing DNA lesions that block RNA polymerase II. Defects in this pathway contribute to neuronal dysfunction.

Companies Developing PD DNA Damage Repair Therapies

Life Biosciences

Focus: PARP inhibition and cellular energy restoration
Lead Candidate: LB-1 (NAD+ booster + PARP inhibitor combination)
Indication: Parkinson's disease
Stage: Phase 2
Mechanism: Dual-action approach combining NAD+ restoration with PARP inhibition to prevent parthanatos
Notes: Founded by David Sinclair, spinout from Harvard/Sinclair Lab
Page: [Life Biosciences](/companies/life-biosciences)

ChromaDex

Focus: NAD+ precursor supplementation
Lead Candidate: NR (Nicotinamide Riboside)
Indication: Parkinson's disease (preclinical)
Stage: Preclinical/Phase 1
Mechanism: NAD+ precursor to boost SIRT1 activity and enhance DNA repair capacity
Notes: Consumer health division sells Tru Niagen, investigating therapeutic applications
Page: [ChromaDex](/companies/chromadex)

Evgen Pharma

Focus: SIRT1 activation through novel sulfonamides
Lead Candidate: SRT2104 (SRT-2183)
Indication: Parkinson's disease
Stage: Phase 1
Mechanism: SIRT1 activator to enhance DNA repair and mitochondrial function
Notes: UK-based, focused on SIRT1 modulation for neurodegeneration
Page: [Evgen Pharma](/companies/evgen-pharma)

Cytochrome Therapeutics

Focus: Mitochondrial DNA repair
Lead Candidate: CT-001 (mitochondria-targeted DNA repair enzyme)
Indication: Parkinson's disease
Stage: Preclinical
Mechanism: Mitochondria-targeted delivery of DNA repair enzymes to address mtDNA damage
Notes: Novel approach targeting mitochondrial genome specifically

Napa Therapeutics

Focus: PINK1-PARKIN pathway and mitochondrial quality control
Lead Candidate: NPT-200
Indication: Parkinson's disease
Stage: Preclinical/IND-enabling
Mechanism: While primarily focused on mitophagy, enhanced mitophagy reduces nuclear DNA damage accumulation from mitochondrial ROS
Notes: Joint venture between Celgene/ BMS and The Michael J. Fox Foundation
Page: [Napa Therapeutics](/companies/napa-therapeutics)

Vandria SA

Focus: Mitochondrial quality control
Lead Candidate: VNA-100
Indication: Parkinson's disease
Stage: Preclinical/IND-enabling
Mechanism: Mitophagy inducer that reduces secondary DNA damage from mitochondrial dysfunction
Notes: Swiss-based, dual programs in AD and PD
Page: [Vandria SA](/companies/vandria)

Clinical Development Landscape

| Company | Candidate | Mechanism | Stage | Status |
|---------|-----------|-----------|-------|--------|
| Life Biosciences | LB-1 | NAD+ + PARP inhibition | Phase 2 | Active |
| ChromaDex | NR | NAD+ precursor | Preclinical | Planning |
| Evgen Pharma | SRT2104 | SIRT1 activator | Phase 1 | Active |
| Cytochrome Therapeutics | CT-001 | mtDNA repair | Preclinical | IND-enabling |
| Napa Therapeutics | NPT-200 | Mitophagy inducer | Preclinical | IND-enabling |
| Vandria | VNA-100 | Mitophagy inducer | Preclinical | IND-enabling |

Emerging Approaches

Small Molecule DNA Repair Enhancers

Pharmaceutical companies are developing small molecules that directly enhance DNA repair enzyme activity:

OGG1 activators: Target 8-oxoguanine glycosylase to accelerate BER
APE1 stabilizers: Enhance apurinic/apyrimidinic endonuclease activity
Pol β modulators: Boost DNA polymerase β for efficient gap-filling

Gene Therapy Approaches

Gene therapy delivery of DNA repair genes:

OGG1 gene delivery: Increase capacity to repair oxidative lesions
APE1 gene delivery: Enhance repair of abasic sites
SIRT1 overexpression: Epigenetic enhancement of DNA repair

Senolytic Approaches

Since senescent cells accumulate DNA damage and secrete pro-inflammatory factors:

Combination approaches: Remove damaged neurons that cannot repair their DNA
Senomorphic: Reduce SASP without eliminating senescent cells

Challenges and Considerations

Blood-Brain Barrier Penetration

Most DNA repair-targeted small molecules must penetrate the BBB. Key considerations:

Lipophilicity and polar surface area
Active transport mechanisms
Prodrug strategies for CNS delivery

Therapeutic Window

PARP inhibition requires careful dosing:

Too much PARP inhibition may impair legitimate DNA repair
Optimal dosing balances neuroprotection with repair capacity

Biomarker Development

Clinical trials need biomarkers for:

DNA damage markers (γH2AX foci, 8-oxodG in CSF)
NAD+ levels in peripheral tissues as proxy
Functional imaging of DNA repair capacity

Cross-References

[DNA Damage Response in Parkinson's Disease](/mechanisms/dna-damage-response-parkinsons)
[DNA Damage Repair Therapy for Neurodegeneration](/therapeutics/dna-damage-repair-therapy)
[PARthanatos Mechanism](/mechanisms/parthanatos)
[Oxidative Stress in Neurodegeneration](/mechanisms/oxidative-stress)
[PARP Inhibitor Companies (AD-focused, may have PD programs)](/companies/ad-parp-inhibitor-companies)
[NAD+ and Sirtuin Modulator Companies](/companies/pd-sirtuin-modulator-companies)
[Mitochondrial Neuroprotection Companies](/companies/pd-mitochondrial-neuroprotection-companies)

📖 View canonical wiki page →

Related Entities

companies-pd-dna-damage-repair-therapeutic-companies

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-pd-dna-damage-repair-therapeutic-companies
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-2bb40f98c105
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-pd-dna-damage-repair-therapeutic-companies'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

91

Outgoing

94

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Parkinson's Disease DNA Damage Repair Therapeutic Companies

Overview

Overview

Key Mechanisms

PARP Inhibition and NAD+ Restoration

Base Excision Repair Enhancement

Nucleotide Excision Repair

Companies Developing PD DNA Damage Repair Therapies

Life Biosciences

ChromaDex

Evgen Pharma

Cytochrome Therapeutics

Napa Therapeutics

Vandria SA

Clinical Development Landscape

Emerging Approaches

Small Molecule DNA Repair Enhancers

Gene Therapy Approaches

Senolytic Approaches

Challenges and Considerations

Blood-Brain Barrier Penetration

Therapeutic Window

Biomarker Development

Cross-References

💬 Discussion